

# Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Renal Cell Carcinoma of Poor or Intermediate Risk: The

Journal of Clinical Oncology

35, 591-597

DOI: [10.1200/jco.2016.70.7398](https://doi.org/10.1200/jco.2016.70.7398)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7â€“11 October 2016. Targeted Oncology, 2016, 11, 705-709.	1.7	0
2	Kidney Cancer: Many Important Advances but Still a Lot to Debate. European Urology Focus, 2016, 2, 565-566.	1.6	0
3	Advances in treatment â€” jostling for pole position. Nature Reviews Clinical Oncology, 2017, 14, 82-84.	12.5	4
4	Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. Expert Review of Clinical Pharmacology, 2017, 10, 1-12.	1.3	3
5	Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. Current Oncology Reports, 2017, 19, 14.	1.8	46
6	Cytoreductive nephrectomy: A medical oncologistâ€™s perspective. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 180-182.	0.8	0
7	Renal cell carcinoma: molecular characterization and evolving treatment paradigms. Current Opinion in Oncology, 2017, 29, 201-209.	1.1	12
8	The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 532.e15-532.e23.	0.8	8
9	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist, 2017, 22, 667-679.	1.9	62
10	Cabozantinib for the treatment of kidney cancer. Expert Review of Anticancer Therapy, 2017, 17, 577-584.	1.1	40
11	Incorporating New Systemic Therapies in Kidney Cancer Treatment. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 703-705.	2.3	4
12	Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms. Current Treatment Options in Oncology, 2017, 18, 18.	1.3	18
13	Treatment for Malignant Pheochromocytomas and Paragangliomas: 5ÂˆYears of Progress. Current Oncology Reports, 2017, 19, 83.	1.8	49
14	Treatment of renal cell carcinoma: Current status and future directions. Ca-A Cancer Journal for Clinicians, 2017, 67, 507-524.	157.7	583
15	Multimodal treatment of advanced renal cancer in 2017. Expert Review of Clinical Pharmacology, 2017, 10, 1395-1402.	1.3	23
16	Clinical development of mTor inhibitors for renal cancer. Expert Opinion on Investigational Drugs, 2017, 26, 1229-1237.	1.9	49
17	Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential. Therapeutic Advances in Medical Oncology, 2017, 9, 627-636.	1.4	11
18	Clinical pharmacology of anti-angiogenic drugs in oncology. Critical Reviews in Oncology/Hematology, 2017, 119, 75-93.	2.0	13

#	ARTICLE	IF	CITATIONS
19	Systemic treatment of renal cell cancer: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2017, 60, 77-89.	3.4	125
20	Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216.		0
22	A step towards predicting checkpoint inhibitor response in kidney cancer. <i>Lancet Oncology</i> , The, 2017, 18, 982-983.	5.1	3
24	A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma. <i>Bioscience Reports</i> , 2017, 37, .	1.1	2
25	Targeted therapies for renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2017, 13, 496-511.	4.1	185
26	My personal highlights of ESMO 2016. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 46-47.	0.3	0
28	The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 169-175.	0.4	8
29	Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 319-329.	1.8	20
30	Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 57-64.	0.2	8
31	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. <i>Canadian Urological Association Journal</i> , 2017, 11, 310-320.	0.3	6
32	Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2801-2811.	2.0	54
33	Reply to B. Rini et al and S. Buti et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1859-1860.	0.8	1
34	Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1858-1859.	0.8	13
35	Aiming for complete responses in renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 428-429.	5.1	0
36	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. <i>Oncologist</i> , 2018, 23, 540-555.	1.9	57
37	Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2018, 10, 109-123.	0.9	27
38	Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 41.	1.8	16
39	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 74, 309-321.	0.9	51

#	ARTICLE	IF	CITATIONS
40	Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 6.	1.3	47
41	Challenging and refining treatment paradigms. <i>Nature Reviews Urology</i> , 2018, 15, 77-78.	1.9	3
42	Combination therapies for patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2018, 19, 281-283.	5.1	4
43	Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor. <i>Pharmacotherapy</i> , 2018, 38, 357-369.	1.2	44
44	Current systemic therapies for metastatic renal cell carcinoma in older adults: A comprehensive review. <i>Journal of Geriatric Oncology</i> , 2018, 9, 265-274.	0.5	5
45	First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy. <i>Current Medical Research and Opinion</i> , 2018, 34, 825-831.	0.9	10
46	Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. <i>Cancer Cell International</i> , 2018, 18, 31.	1.8	63
47	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 298-304.	0.9	41
48	Landmark Trials in Renal Cancer. <i>Kidney Cancer</i> , 2018, 2, 11-21.	0.2	0
49	Renal cell carcinoma in one year: Going inside the news of 2017 – A report of the main advances in RCC cancer research. <i>Cancer Treatment Reviews</i> , 2018, 67, 29-33.	3.4	8
50	Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges. <i>Clinical Medicine Insights Urology</i> , 2018, 11, 117956111876575.	0.4	1
51	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018, 94, 115-125.	1.3	280
52	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
53	Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 461-467.	1.5	9
54	Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 29-34.	0.9	11
55	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. <i>Cancer</i> , 2018, 124, 306-314.	2.0	23
56	Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 11.e13-11.e21.	0.8	24
58	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2018, 73, 311-315.	0.9	138

#	ARTICLE	IF	CITATIONS
59	Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. <i>Medical Oncology</i> , 2018, 35, 4.	1.2	17
60	Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 306-315.	1.9	56
61	Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type. <i>Annual Review of Medicine</i> , 2018, 69, 209-221.	5.0	7
62	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 765-772.	0.8	117
63	Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1588-1593.	0.8	39
64	Personalized Management of Advanced Kidney Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 330-341.	1.8	25
65	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3615-3623.	0.8	65
66	Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. <i>Journal of Clinical Oncology</i> , 2018, 36, 3529-3532.	0.8	0
67	Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer. <i>Oncology Letters</i> , 2019, 17, 1547-1550.	0.8	0
71	The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria. <i>Oncotarget</i> , 2018, 9, 27752-27759.	0.8	16
72	Biomarkers in renal-cell carcinoma: building on clinical paradigms. <i>Lancet Oncology</i> , The, 2018, 19, 1560-1561.	5.1	0
73	Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 1114.	1.1	26
74	Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports. <i>Journal of Medical Case Reports</i> , 2018, 12, 351.	0.4	23
75	The role of tumor microenvironment in resistance to anti-angiogenic therapy. <i>F1000Research</i> , 2018, 7, 326.	0.8	47
76	Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date. <i>Cancer Management and Research</i> , 2018, Volume 10, 3773-3780.	0.9	3
77	Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis. <i>Kidney Cancer</i> , 2018, 2, 115-121.	0.2	1
78	A comprehensive review of protein kinase inhibitors for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1249-1270.	1.1	164
79	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. <i>Journal of Hematology and Oncology</i> , 2018, 11, 120.	6.9	333

#	ARTICLE	IF	CITATIONS
80	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 5773-5782.	0.5	17
82	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
83	Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. <i>F1000Research</i> , 2018, 7, 1148.	0.8	28
84	Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. <i>European Journal of Cancer</i> , 2018, 104, 188-194.	1.3	58
85	Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2018, 5, 1-5.	0.2	20
86	Treating patients with renal cell carcinoma and bone metastases. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1135-1143.	1.1	9
87	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
88	The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. <i>Immunotherapy</i> , 2018, 10, 1047-1052.	1.0	8
90	Advances in the Treatment of Metastatic Renal Cell Carcinoma. <i>Cancer Treatment and Research</i> , 2018, 175, 127-137.	0.2	6
91	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	0.9	31
92	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e317-e326.	5.1	46
93	Tivozanib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1021-1025.	0.9	16
95	Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1355-1364.	1.9	280
96	Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints. <i>Investigational New Drugs</i> , 2018, 36, 1143-1146.	1.2	4
97	Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5534-5542.	3.2	15
98	Renal Cell Carcinoma in von Hippel-Lindau Disease From Tumor Genetics to Novel Therapeutic Strategies. <i>Frontiers in Pediatrics</i> , 2018, 6, 16.	0.9	38
99	Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. <i>Recent Results in Cancer Research</i> , 2018, 211, 67-75.	1.8	61
100	Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer. <i>Frontiers in Endocrinology</i> , 2018, 9, 277.	1.5	48

#	ARTICLE	IF	CITATIONS
101	Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2018, 70, 127-137.	3.4	276
102	When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 80.	0.4	7
103	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	0.9	30
104	Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e521-e523.	0.9	17
105	Lenvatinib for the treatment of kidney cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 511-518.	1.1	13
106	Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 171-179.	1.0	18
107	The role of tivozanib in advanced renal cell carcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1113-1124.	1.1	14
108	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 70, 112-117.	3.4	17
109	Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 457-465.	0.3	18
110	Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 947-957.	1.4	46
111	Cytoreductive Nephrectomy " Patient Selection Is Key. <i>New England Journal of Medicine</i> , 2018, 379, 481-482.	13.9	88
112	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 417-427.	13.9	684
113	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 29-39.	2.3	43
114	Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies. , 2019, , 25-60.		2
115	Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 149-154.	0.5	14
117	Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. <i>Future Oncology</i> , 2019, 15, 2337-2348.	1.1	15
118	Mit Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. <i>Cancers</i> , 2019, 11, 1110.	1.7	79
119	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019, 24, 1497-1501.	1.9	22

#	ARTICLE	IF	CITATIONS
120	Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro. <i>Chemical Research in Toxicology</i> , 2019, 32, 1583-1590.	1.7	11
121	Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data. <i>Targeted Oncology</i> , 2019, 14, 405-416.	1.7	35
122	Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis. <i>Future Oncology</i> , 2019, 15, 3987-4001.	1.1	6
123	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019, 13, 343-54.	0.3	10
124	Response of Primary Renal Cell Carcinoma to Systemic Therapy. <i>European Urology</i> , 2019, 76, 852-860.	0.9	9
125	First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. <i>Targeted Oncology</i> , 2019, 14, 639-645.	1.7	14
126	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019, 11, 1505.	1.7	120
127	Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma. <i>Cancer</i> , 2019, 125, 4148-4157.	2.0	21
128	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
129	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
130	OSSMAR: An Observational Study to Describe the Use of Sunitinib in Real-Life Practice for the Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Global Oncology</i> , 2019, 5, 1-10.	0.5	4
131	The Changing Therapeutic Landscape of Metastatic Renal Cancer. <i>Cancers</i> , 2019, 11, 1227.	1.7	49
132	Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis. <i>EBioMedicine</i> , 2019, 47, 78-88.	2.7	24
133	Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios. <i>International Urology and Nephrology</i> , 2019, 51, 2107-2117.	0.6	2
134	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 505-514.	2.6	50
135	Management of metastatic renal cell carcinoma: The complexity of choice. <i>EBioMedicine</i> , 2019, 47, 2-3.	2.7	1
136	Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1181-e1184.	0.9	0
137	Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and) Tj ETQq1 1 0.784314 rgBT /Overlo 4712.	1.8	48



#	ARTICLE	IF	CITATIONS
138	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2019, 2, 708-715.	2.6	64
139	S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma. <i>Cancer Research</i> , 2019, 79, 5758-5768.	0.4	39
140	Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 259-271.	1.1	7
141	Targeting angiogenesis in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 245-257.	1.1	12
142	Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e454-e460.	0.9	14
143	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
144	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e526-e533.	0.9	9
145	What Comes After Immuno-Oncology Therapy for Kidney Cancer?. <i>Kidney Cancer</i> , 2019, 3, 93-102.	0.2	4
146	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019, 11, 830.	1.7	29
147	Personalized approach to systemic therapy of renal cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 179-188.	0.4	0
148	Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 2581-2582.	13.9	8
150	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 291-298.	0.9	30
151	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5202-5211.	3.2	26
152	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 485-496.	1.0	10
153	Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 114, 67-75.	1.3	88
154	Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy. <i>Cancers</i> , 2019, 11, 608.	1.7	5
155	The use of cytoreductive nephrectomy in patients with renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 405-411.	1.1	2
156	Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 411-418.	0.8	16

#	ARTICLE	IF	CITATIONS
158	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" International Journal of Molecular Sciences, 2019, 20, 1901.	1.8	41
159	Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma. Case Reports in Urology, 2019, 2019, 1-4.	0.1	17
160	Towards individualized therapy for metastatic renal cell carcinoma. Nature Reviews Clinical Oncology, 2019, 16, 621-633.	12.5	148
161	Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy. Case Reports in Urology, 2019, 2019, 1-5.	0.1	9
162	Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis. Future Oncology, 2019, 15, 2175-2190.	1.1	7
163	Economic burden of renal cell carcinoma among older adults in the targeted therapy era. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 356.e19-356.e28.	0.8	12
164	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. International Journal of Cancer, 2019, 145, 1991-2001.	2.3	32
165	Cell-free Circulating Tumor DNA (ctDNA) in Metastatic Renal Cell Carcinoma (mRCC): Current Knowledge and Potential Uses. Kidney Cancer, 2019, 3, 7-13.	0.2	3
166	C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas. Cells, 2019, 8, 272.	1.8	21
168	Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. Canadian Urological Association Journal, 2019, 13, E377-E381.	0.3	3
169	Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?. Future Oncology, 2019, 15, 925-927.	1.1	0
170	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy, 2019, 11, 631-643.	1.0	38
171	Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Molecular Cancer Therapeutics, 2019, 18, 1001-1011.	1.9	34
172	The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions. Current Treatment Options in Oncology, 2019, 20, 41.	1.3	25
174	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clinical Drug Investigation, 2019, 39, 503-519.	1.1	26
175	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 529.e1-529.e7.	0.8	5
176	Overview of current and future systemic therapy for metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 395-403.	0.6	38
177	Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension. Cardiovascular Research, 2019, 115, 904-914.	1.8	63

#	ARTICLE	IF	CITATIONS
178	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.	5.1	124
179	Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. <i>Medical Oncology</i> , 2019, 36, 29.	1.2	0
180	First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 491.	3.4	123
181	Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. <i>Drugs and Aging</i> , 2019, 36, 395-401.	1.3	5
182	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e513-e521.	0.9	31
183	Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S137-S137.	0.7	9
184	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. <i>Oncologist</i> , 2019, 24, 1469-1478.	1.9	25
185	The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer. <i>Kidney Cancer</i> , 2019, 3, 81-91.	0.2	1
186	Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, S585-S588.	0.4	1
187	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 338-348.	1.9	34
188	Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S385-S385.	0.7	2
189	Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?. <i>Annals of Translational Medicine</i> , 2019, 7, S275-S275.	0.7	0
192	Incidence and risk of fatigue in cancer patients treated with MET inhibitors. <i>Medicine (United States)</i> , 2019, 98, e15522.	0.4	5
193	Second-line therapy in metastatic renal cell cancer—how do we treat after immuno-oncology drugs?. Memo - Magazine of European Medical Oncology, 2019, 12, 339-341.	0.3	1
194	Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. <i>Oncologist</i> , 2019, 24, e702-e708.	1.9	70
195	Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 121-130.	1.9	21
196	A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2019, 152, 548-553.	0.6	23
197	The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 8.	1.2	16

#	ARTICLE	IF	CITATIONS
198	TKIs in Renal Cell Carcinoma. , 2019, , 551-563.		0
199	Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases. <i>European Urology</i> , 2019, 75, 352-353.	0.9	32
200	Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greeceâ€”the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 491-501.	0.7	1
201	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019, 42, 211-233.	1.4	76
202	Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Nonâ€”Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e317-e328.	1.1	26
203	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2019, 108, 33-40.	1.3	96
204	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. <i>Future Oncology</i> , 2019, 15, 563-565.	1.1	2
205	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 297-310.	5.1	207
206	Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. <i>Oncologist</i> , 2019, 24, 143-145.	1.9	3
207	Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 111-128.	0.9	138
208	Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Nonâ€”small-cell Lung Carcinoma. <i>Clinical Lung Cancer</i> , 2019, 20, 74-81.e1.	1.1	19
209	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 411-419.	1.0	4
210	Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 46-57.e5.	0.9	130
211	Metastatic Pheochromocytoma: Spinning Towards More Promising Treatment Options. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 117-128.	0.6	40
212	Cancer of the Kidney. , 2020, , 1361-1381.e4.		0
213	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381.	2.6	59
214	Using a Benefitâ€”Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 495-506.	2.3	4
215	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 141-150.	1.5	14

#	ARTICLE	IF	CITATIONS
216	What Do International Guidelines Say About First-line Therapy for Clear-cell Metastatic Renal Cell Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 48-52.	1.6	5
217	Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1108-1116.	1.2	11
218	A review of checkpoint inhibitors in the management of renal cell carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 445-458.	0.5	9
219	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39.	0.2	2
220	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100166.	0.7	23
221	Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2020, 37, 730-744.	1.3	16
222	Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC). <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2571-2581.	1.2	21
223	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 43.e13-43.e20.	0.8	8
224	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	5.1	160
226	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
227	Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment. <i>Cancers</i> , 2020, 12, 2697.	1.7	11
229	Targeted therapy for metastatic renal cell carcinoma. <i>The Cochrane Library</i> , 2020, 2020, CD012796.	1.5	23
230	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 2307-2328.	1.1	17
231	The Immunotherapy Revolution in Kidney Cancer Treatment. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 419-431.	1.0	17
232	c-Met expression in renal cell carcinoma with bone metastases. <i>Journal of Bone Oncology</i> , 2020, 25, 100315.	1.0	10
233	Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1389-1406.	1.9	4
234	Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib. <i>Cancer</i> , 2020, 126, 5210-5212.	2.0	1
235	Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). <i>Cancer</i> , 2020, 126, 5311-5318.	2.0	13

#	ARTICLE	IF	CITATIONS
236	Targeting the HIF2-VEGF axis in renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 1519-1530.	15.2	248
237	Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. <i>Cancer Treatment Reviews</i> , 2020, 89, 102062.	3.4	14
238	Tyrosine Kinase Receptors in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8529.	1.8	46
239	Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors. , 2020, , 403-420.		0
240	Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1246.	1.3	19
241	Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 584.	1.8	40
242	Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 1507-1517.	0.9	11
243	Cabozantinib in advanced renal cell carcinoma: A phase III, open-label, single-arm study of Japanese patients. <i>International Journal of Urology</i> , 2020, 27, 952-959.	0.5	17
244	Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry. <i>Future Oncology</i> , 2020, 16, 2939-2948.	1.1	8
245	Advanced Non-Clear Cell Kidney Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 441-447.	1.0	1
246	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	2.0	18
247	What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. <i>BMJ Open</i> , 2020, 10, e034626.	0.8	13
248	The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review. <i>Future Oncology</i> , 2020, 16, 2879-2896.	1.1	3
249	&lt;p&gt;Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 7321-7330.	0.9	24
250	Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers. <i>ESMO Open</i> , 2020, 5, e000862.	2.0	41
251	Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 831-840.	1.1	3
252	Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study. <i>Future Oncology</i> , 2020, 16, 3045-3060.	1.1	7
253	Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib. <i>Targeted Oncology</i> , 2020, 15, 673-679.	1.7	9

#	ARTICLE	IF	CITATIONS
254	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. <i>European Urology Open Science</i> , 2020, 22, 61-73.	0.2	11
255	Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 3750.	1.7	10
256	Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1623-1630.	0.5	0
257	Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 61-69.	0.2	1
259	Target Therapy for Kidney Cancer. , 2020, , .		0
260	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. <i>Journal of Clinical Medicine</i> , 2020, 9, 1508.	1.0	3
261	Tumor Endothelial Cellâ€”A Biological Tool for Translational Cancer Research. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3238.	1.8	22
262	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 664.	1.3	19
263	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1594.	1.0	49
264	Immune Checkpoint Inhibitors in Genitourinary Malignancies. <i>Current Oncology</i> , 2020, 27, 69-77.	0.9	13
265	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 128.	0.8	3
266	The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100183.	0.7	8
267	An Electronic Health Record Text Mining Tool to Collect Realâ€”World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 644-652.	2.3	19
268	Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 293-303.	0.8	25
269	A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?. <i>Anti-Cancer Drugs</i> , 2020, 31, 211-215.	0.7	6
270	Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102971.	2.0	7
271	&lt;p&gt;Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4021-4034.	1.0	5
272	Cabozantinib as an emerging treatment for sarcoma. <i>Current Opinion in Oncology</i> , 2020, 32, 321-331.	1.1	14

#	ARTICLE	IF	CITATIONS
273	&lt;p&gt;Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 3741-3749.	0.9	15
274	Sequencing Therapies for Metastatic Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 305-318.	0.8	14
275	Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review. Clinical Genitourinary Cancer, 2020, 18, e688-e691.	0.9	11
276	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nature Reviews Urology, 2020, 17, 271-291.	1.9	32
277	An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). Critical Reviews in Oncology/Hematology, 2020, 149, 102921.	2.0	8
278	Perioperative therapies for urological cancers. Japanese Journal of Clinical Oncology, 2020, 50, 357-367.	0.6	3
279	Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. Clinical Genitourinary Cancer, 2020, 18, e588-e597.	0.9	11
280	Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. Cancers, 2020, 12, 808.	1.7	10
281	First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis. Clinical Genitourinary Cancer, 2020, 18, 244-251.e4.	0.9	16
282	Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective. International Journal of Molecular Sciences, 2020, 21, 4691.	1.8	40
283	Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Cancers, 2020, 12, 1673.	1.7	13
284	Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 271-280.	0.8	2
285	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2020, 21, 1099-1109.	5.1	59
286	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. Pathology, 2020, 52, 297-309.	0.3	35
287	New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. Journal of Clinical Medicine, 2020, 9, 565.	1.0	35
288	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome&quot;Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2020, 3, 530-539.	2.6	29
289	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 408.	1.7	32
290	A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus. Clinical and Translational Oncology, 2020, 22, 1565-1579.	1.2	1



#	ARTICLE	IF	CITATIONS
291	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020, 25, 422-430.	1.9	12
292	A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. <i>Current Medical Research and Opinion</i> , 2020, 36, 625-635.	0.9	4
293	SEOM clinical guideline for treatment of kidney cancer (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 256-269.	1.2	18
294	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). <i>Clinical Cancer Research</i> , 2020, 26, 2477-2486.	3.2	16
296	Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e374-e385.	0.9	12
297	Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 187-196.	1.8	26
298	On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 418-435.	1.8	16
299	Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2201-2207.	0.9	4
300	Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. <i>Current Opinion in Oncology</i> , 2020, 32, 240-249.	1.1	15
301	Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture <i>In Vitro</i> and Reduces Bone Osteolysis <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1266-1278.	1.9	9
302	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 481-490.	1.2	11
303	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. <i>World Journal of Urology</i> , 2021, 39, 829-837.	1.2	3
304	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 32-40.	0.9	17
305	First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. <i>International Journal of Cancer</i> , 2021, 148, 950-960.	2.3	5
306	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. <i>Trends in Cancer</i> , 2021, 7, 15-28.	3.8	61
308	Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. <i>Future Oncology</i> , 2021, 17, 241-254.	1.1	4
309	Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. <i>Cancer</i> , 2021, 127, 938-945.	2.0	11
310	A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 35-49.	0.7	18

#	ARTICLE	IF	CITATIONS
311	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021, 4, 274-281.	2.6	7
312	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 102-111.	2.6	26
313	Are tyrosine kinase inhibitors fit for purpose in the treatment of metastatic papillary renal cell carcinoma?. <i>Journal of Clinical Urology</i> , 0, , 205141582098766.	0.1	0
314	Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100393.	0.7	2
315	Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 15.	1.3	13
316	Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>JAMA Network Open</i> , 2021, 4, e2034201.	2.8	4
317	New approaches to first-line treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110347.	1.4	25
318	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	15.2	46
319	First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. <i>ESMO Open</i> , 2021, 6, 100030.	2.0	35
320	Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 966-975.	0.6	12
321	Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 622134.	1.3	4
322	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	13.9	961
323	Management of locally advanced renal cell carcinoma. <i>AME Medical Journal</i> , 0, 6, 5-5.	0.4	2
324	Identification of a Risk Stratification Model to Predict Overall Survival and Surgical Benefit in Clear Cell Renal Cell Carcinoma With Distant Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 630842.	1.3	8
325	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.3	11
326	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	2.0	32
327	Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 723-742.	1.1	13
328	Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021, 5, 21-29.	0.2	3

#	ARTICLE	IF	CITATIONS
330	Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies. <i>Oncoscience</i> , 2021, 8, 40-45.	0.9	1
331	Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 693-703.	1.1	3
332	Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. <i>Oncologist</i> , 2021, 26, 476-482.	1.9	19
333	Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110055.	0.5	5
334	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 657639.	1.3	18
336	Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103293.	2.0	7
337	A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 712-723.	0.9	43
338	Immune Checkpoint Inhibitors in Prostate Cancer. <i>Cancers</i> , 2021, 13, 2187.	1.7	48
339	Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100267.	3.3	4
340	Poster Exhibit 2: Non-prostate Genitourinary Cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, S84-98.	0.3	0
341	Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 186.	3.5	77
342	Osteonecrosis mandibular en relación al empleo de cabozantinib. <i>Medicina Clínica</i> , 2021, 156, 627-628.	0.3	1
343	HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. <i>Oncogene</i> , 2021, 40, 4625-4651.	2.6	81
344	Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. <i>Future Oncology</i> , 2021, 17, 2325-2338.	1.1	3
345	Jaw osteonecrosis related to cabozantinib. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 627-628.	0.1	1
346	Metachronous Renal Cell Carcinoma: A Rare Presentation of Adrenal Crisis. <i>Cureus</i> , 2021, 13, e15965.	0.2	0
347	Circulating Levels of the Interferon- $\gamma$ -Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. <i>Cancers</i> , 2021, 13, 2849.	1.7	10
348	Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. <i>Current Oncology Reports</i> , 2021, 23, 100.	1.8	26

#	ARTICLE	IF	CITATIONS
349	Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer. <i>Journal of Genetics and Genomics</i> , 2021, 48, 552-559.	1.7	8
350	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 168-178.	2.3	14
351	Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. <i>ESMO Open</i> , 2021, 6, 100223.	2.0	18
352	Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC. <i>Cancers</i> , 2021, 13, 4140.	1.7	14
353	What is the role of real-world data in metastatic renal cell cancer?. <i>Future Oncology</i> , 2021, 17, 3905-3909.	1.1	1
354	Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma. <i>Biology</i> , 2021, 10, 781.	1.3	3
355	Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1183-1192.	1.1	0
356	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-14.	0.9	2
357	Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. <i>European Urology Oncology</i> , 2022, 5, 125-133.	2.6	10
358	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro) Tj ETQq1 1,0784314 rgBT /Ove 0,9	0,9	3
359	Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 80-87.	0.9	7
360	Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer. <i>International Journal of Cancer</i> , 2022, 150, 308-316.	2.3	8
361	The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutrition. <i>Journal of Neurosurgery: Spine</i> , 2021, 35, 356-365.	0.9	6
362	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	0.8	69
363	Metastatic Renal Cell Carcinoma to the Spine: Outcomes and Morbidity: Single-Center Experience. <i>World Neurosurgery</i> , 2021, 154, e398-e405.	0.7	4
364	Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 664-677.	0.8	7
365	Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab. <i>In Vivo</i> , 2021, 35, 1743-1747.	0.6	5
366	Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 375.	1.7	9

#	ARTICLE	IF	CITATIONS
367	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.	1.3	22
368	A Simple Reversed Phase High Performance Liquid Chromatography Method for the Estimation of Related Substances, Assay of Cabozantinib and Nivolumab and its Application to Dissolution Studies. , 2021, 83, .		1
369	Targeted Treatment of Renal Cell Carcinoma. , 2020, , 399-408.		1
370	Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma. <i>European Journal of Medicinal Chemistry</i> , 2020, 200, 112482.	2.6	14
371	Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. , 2020, 8, e000319.		67
372	Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease. <i>Forum of Clinical Oncology</i> , 2017, 8, 15-21.	0.1	1
373	Antiangiogenic therapies for pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2020, 27, R239-R254.	1.6	23
374	Cabozantinib: from studies to clinical practice. <i>Onkourologiya</i> , 2019, 15, 28-41.	0.1	6
375	Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. <i>Oncotarget</i> , 2017, 8, 75478-75487.	0.8	26
376	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , 2017, 8, 103428-103436.	0.8	19
377	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2020, 11, 4582-4592.	0.8	14
378	Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers. <i>Cancers</i> , 2020, 12, 2768.	1.7	2
379	Combination drug regimens for metastatic clear cell renal cell carcinoma. <i>World Journal of Clinical Oncology</i> , 2020, 11, 541-562.	0.9	19
380	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	2.3	185
381	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1815.	3.4	40
382	Evolving Patterns of Metastasis in Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2021, 8, 13-19.	0.2	1
383	Evolving cancer-niche interactions and therapeutic targets during bone metastasis. <i>Nature Reviews Cancer</i> , 2022, 22, 85-101.	12.8	47
384	Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States. <i>Advances in Therapy</i> , 2021, 38, 5662-5670.	1.3	3

#	ARTICLE	IF	CITATIONS
385	Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 125, 1533-1543.	2.9	13
386	Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 94-94.e10.	0.9	3
387	Metastasectomy in kidney cancer: current indications and treatment approaches. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 266-275.	0.5	4
388	Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma. , 2017, , 1-20.		0
389	Quelle stratÃ©gie thÃ©rapeutique pour les stades mÃ©tastatiques ?. <i>Oncologie</i> , 2018, 20, 211-219.	0.2	0
391	Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to theÃ©Clinic. , 2019, , 419-443.		0
392	Kidney Cancer: From Basics to Immunotherapy. , 2019, , 625-657.		0
393	Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma. , 2019, , 595-614.		0
394	Oncurologistâ€™s opinion on the results of the CARMENA study. <i>Malignant Tumours</i> , 2019, 8, 26-29.	0.1	0
395	Landmark Trials in Selected Genitourinary Malignancies. , 2019, , 75-121.		0
396	Anti-angiogenics in Kidney Cancer Therapy. , 2019, , 569-578.		0
397	The power of meta-analysis in therapeutic decision making for advanced kidney cancer. <i>Translational Cancer Research</i> , 2019, 8, 7-10.	0.4	0
398	Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 333-339.	0.2	1
399	Resolution on the results of the Expert Council on the treatment of advanced and metastatic clear cell renal cell carcinoma. <i>Onkourologiya</i> , 2019, 15, 150-153.	0.1	1
400	Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 483-493.	0.2	0
401	Looking beyond cancer for cabozantinib-induced cardiotoxicity: evidence of absence or absence of evidence?. <i>Annals of Translational Medicine</i> , 2019, 7, S121-S121.	0.7	0
402	Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now?. <i>Annals of Translational Medicine</i> , 2019, 7, S229-S229.	0.7	1
403	Defining an Individualized Treatment Strategy for Metastatic Renal Cancer. , 2020, , 437-452.		0

#	ARTICLE	IF	CITATIONS
404	Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis. <i>Oncology Letters</i> , 2020, 19, 261-270.	0.8	1
405	Renal Cell Carcinoma: Oncologist Point of View. , 2020, , 21-29.		0
408	Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms. , 2020, , 163-187.		0
409	Latest progress in molecular biology and treatment in genitourinary tumours. <i>Clinical and Translational Oncology</i> , 2020, 22, 2175-2195.	1.2	2
410	Retrospective comparison of the different immune combinations in metastatic renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 839-839.	0.7	0
411	Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. <i>Acta Oncológica</i> , 2022, 61, 22-29.	0.8	17
412	CheckMate 214 trial: Immune checkpoint regulators for advanced renal cell carcinoma. <i>Indian Journal of Urology</i> , 2020, 36, 231.	0.2	4
413	Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. <i>Anti-Cancer Drugs</i> , 2021, 32, 74-81.	0.7	4
415	Cáncer renal avanzado, perfiles para los nuevos tratamientos. <i>Medicina Clinica Practica</i> , 2022, 5, 100277.	0.2	0
416	Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma. , 2021, 7, .		16
417	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 115-121.	1.1	5
418	Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. <i>Clinical Immunology</i> , 2021, 232, 108876.	1.4	4
419	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncológica</i> , 2022, 61, 52-57.	0.8	0
421	Targeted Therapies for Treatment of Metastatic Renal Cell Carcinoma. , 2021, , 239-254.		0
424	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. <i>Onkologie (Czech Republic)</i> , 2020, 14, 199-204.	0.0	0
425	Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2022, 166, 97-104.	0.2	2
426	From Radical to Partial Nephrectomy in the Setting of Solitary Functioning Kidney: Neoadjuvant Treatment of Renal Cell Carcinoma. <i>Reviews in Urology</i> , 2020, 22, 126-129.	0.9	0
427	The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Indian Journal of Urology</i> , 2021, 37, 13-19.	0.2	1

#	ARTICLE	IF	CITATIONS
428	Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma. <i>Current Oncology</i> , 2021, 28, 5019-5024.	0.9	0
429	Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. <i>Future Oncology</i> , 2022, 18, 21-33.	1.1	5
430	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5856.	1.7	39
431	Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 53-59.	0.9	4
432	Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?. <i>Current Oncology Reports</i> , 2021, 23, 147.	1.8	15
433	Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. <i>ESMO Open</i> , 2021, 6, 100312.	2.0	17
434	Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?. <i>Expert Opinion on Investigational Drugs</i> , 2021, , 1-9.	1.9	4
435	Dose adjustment for tyrosine kinase inhibitors in non-small cell lung cancer patients with hepatic or renal function impairment (Review). <i>Oncology Reports</i> , 2020, 45, 413-426.	1.2	9
436	Systemtherapie beim metastasierten Nierenzellkarzinom. , 2021, , 407-473.		0
437	Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study. <i>Cancer</i> , 2022, 128, 1429-1438.	2.0	21
438	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.	2.3	248
439	The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103602.	2.0	5
440	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 292-303.	5.1	42
441	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. <i>Cancer Treatment Reviews</i> , 2022, 103, 102333.	3.4	21
442	Global management of brain metastasis from renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103600.	2.0	2
443	Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology Open Science</i> , 2022, 37, 14-26.	0.2	48
444	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210795.	1.4	10
445	Overview of clinical management for older patients with renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 665-681.	0.6	2



#	ARTICLE	IF	CITATIONS
446	First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. <i>Drugs</i> , 2022, 82, 439-453.	4.9	3
447	A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma. <i>Diagnostics</i> , 2022, 12, 539.	1.3	2
448	Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2022, 17, 193-201.	1.7	2
449	The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2022, 34, 234-242.	1.1	16
450	Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2022, 22, 228.	1.1	11
451	Tumour endothelial cells for translational research and therapeutics. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	0
452	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2022, 11, 3106-3114.	1.3	10
453	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. <i>Cancers</i> , 2022, 14, 1406.	1.7	13
454	Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management. <i>Current Treatment Options in Oncology</i> , 2022, 23, 609-629.	1.3	1
455	Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. <i>International Journal of Urology</i> , 2022, 29, 494-501.	0.5	8
456	Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022, 6, 69-79.	0.2	2
457	Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 3593-3600.	0.3	1
458	Recent Advances in Medical Therapy for Urological Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 746922.	1.3	8
459	Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy. <i>Biomaterials</i> , 2022, 283, 121454.	5.7	9
460	Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-9.	2.3	8
461	“The first ones now, will later be last” understanding the importance of historical context when reading ESMO-MCBS scores. <i>ESMO Open</i> , 2022, 7, 100413.	2.0	0
462	Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma. <i>Integrative Biology (United Kingdom)</i> , 2021, 13, 259-268.	0.6	4
463	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. <i>Clinical Cancer Research</i> , 2022, 28, 748-755.	3.2	9

#	ARTICLE	IF	CITATIONS
464	CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates. <i>Frontiers in Oncology</i> , 2021, 11, 744107.	1.3	11
465	Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States. <i>Frontiers in Pharmacology</i> , 2021, 12, 736860.	1.6	4
466	Hybrid Therapy (Surgery and Radiosurgery) for the Treatment of Renal Cell Carcinoma Spinal Metastases. <i>Neurosurgery</i> , 2022, 90, 199-206.	0.6	10
467	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN± ± Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.	3.2	8
468	FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 756843.	1.3	8
469	Prognostic Biomarkers in Patients with Renal Cell Carcinoma: Where are We Going from Here?. <i>Trends in Oncology</i> , 2020, 2, 1-10.	0.0	0
471	Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 910.	3.4	20
473	The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Indian Journal of Urology</i> , 2021, 37, 13.	0.2	4
474	Developments in personalized therapy for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 647-655.	1.1	6
475	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The "retry" study from the Italian Group of Onco-Nephrology (G.I.O.N.). <i>Journal of Onco-Nephrology</i> , 2022, 6, 107-114.	0.3	1
476	Identification of multi-target anti-cancer agents from TCM formula by in silico prediction and in vitro validation. <i>Chinese Journal of Natural Medicines</i> , 2022, 20, 332-351.	0.7	2
478	Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients. <i>Translational Andrology and Urology</i> , 2022, 11, 694-709.	0.6	2
479	Reduced CDH16 expression is linked to poor prognosis in clear cell renal cell carcinoma 16. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	1
480	Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment. <i>Anticancer Research</i> , 2022, 42, 3151-3158.	0.5	4
481	An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 619-632.	0.9	5
482	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 454-489.	157.7	13
483	A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 473-481.	0.9	2
484	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 2957-2995.	0.8	97

#	ARTICLE	IF	CITATIONS
486	Cabozantinib for the treatment of solid tumors: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211071.	1.4	17
487	Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. <i>Cancers</i> , 2022, 14, 3214.	1.7	2
488	Case report: treatment of metastatic renal cell carcinoma with nivolumab plus cabozantinib in routine clinical practice. <i>Malignant Tumours</i> , 2022, 12, 45-51.	0.1	0
489	Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 3850-3861.	3.2	1
490	Renal Tumors. , 2023, , 285-308.		0
491	CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). <i>Clinical Genitourinary Cancer</i> , 2023, 21, 106.e1-106.e8.	0.9	7
492	PANK1 associates with cancer metabolism and immune infiltration in clear cell renal cell carcinoma: a retrospective prognostic study based on the TCGA database. <i>Translational Cancer Research</i> , 2022, 11, 2321-2337.	0.4	1
493	Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 0, , .	2.9	4
495	Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past?. <i>Cancers</i> , 2022, 14, 3777.	1.7	6
496	Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review. <i>Cancer Treatment Reviews</i> , 2022, 110, 102453.	3.4	2
497	Cabozantinib combination therapy for the treatment of solid tumors: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211086.	1.4	3
498	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
499	Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>Journal of Kidney Cancer and VHL</i> , 2022, 9, 29-40.	0.2	4
500	Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 1411.	3.4	37
501	Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 1419-1428.	0.5	4
502	PLK4 Is a Potential Biomarker for Abnormal Tumor Proliferation, Immune Infiltration, and Prognosis in ccRCC. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-21.	0.7	1
503	Establishment of a ccRCC patient-derived chick chorioallantoic membrane model for drug testing. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
504	Role of copper ionophore-induced death in immune microenvironment and clinical prognosis of ccRCC: An integrated analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3

#	ARTICLE	IF	CITATIONS
506	Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	0
507	IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time. <i>Seminars in Oncology</i> , 2022, 49, 394-399.	0.8	2
508	Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
509	Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12634.	1.8	0
511	Preclinical Characterization of XLO92, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 179-191.	1.9	3
512	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 131-149.	0.4	3
513	Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety. <i>Cancer Medicine</i> , 0, , .	1.3	0
514	Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. <i>Biomedicines</i> , 2022, 10, 3172.	1.4	2
515	Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2023, 30, 705-713.	0.5	1
516	SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma. <i>Discover Oncology</i> , 2022, 13, .	0.8	5
517	Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. <i>Neurospine</i> , 2022, 19, 978-993.	1.1	3
518	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline Q&A. <i>JCO Oncology Practice</i> , 2023, 19, 127-131.	1.4	1
519	The Role of Immunotherapy in Renal Cell Carcinoma. , 2023, , 1-31.		0
520	Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. <i>Cancers</i> , 2023, 15, 529.	1.7	3
521	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
522	Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. <i>OncoTargets and Therapy</i> , 0, Volume 16, 49-64.	1.0	1
523	Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC). <i>Uro</i> , 2023, 3, 117-131.	0.3	2
524	Metastasis in renal cell carcinoma: Biology and treatment. <i>Advances in Cancer Biology Metastasis</i> , 2023, 7, 100094.	1.1	0

#	ARTICLE	IF	CITATIONS
525	Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation. <i>Hypertension</i> , 2023, 80, 685-710.	1.3	7
526	The Gut Microbiome and Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 1502.	1.0	3
527	Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2023, , .	2.6	3
528	SLC9A1 Binding mTOR Signaling Pathway-Derived Risk Score Predicting Survival and Immune in Clear Cell Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2023, 2023, 1-14.	0.6	0
529	Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2023, , .	0.9	1
530	Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study. <i>Cancers</i> , 2023, 15, 1393.	1.7	1
531	Overexpression of complement C5a indicates poor survival and therapeutic response in metastatic renal cell carcinoma. <i>International Journal of Biological Markers</i> , 2023, 38, 124-132.	0.7	1
532	The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. <i>European Journal of Pharmacology</i> , 2023, 949, 175586.	1.7	27
533	Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”—A Multicenter Retrospective Review. <i>Clinical Genitourinary Cancer</i> , 2023, , .	0.9	2
534	Treatment strategies for clear cell renal cell carcinoma: Past, present and future. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	6
535	Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 545-554.	1.1	1
536	Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 461-469.	1.1	1
537	Active Pharmacovigilance Study: A Follow-Up Model of Oral Anti-Cancer Drugs under Additional Monitoring. <i>Current Oncology</i> , 2023, 30, 4139-4152.	0.9	0
538	Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	4
539	Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 710-726.	2.5	2
547	Cabozantinib-induced serum creatine kinase elevation and rhabdomyolysis: a retrospective case series. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 92, 235-240.	1.1	2
566	Management of Metastatic Renal Cell Carcinoma. , 2023, , 41-52.		0
568	Predictive Biomarkers in Advanced Renal Cell Carcinoma. , 2023, , 251-268.		0

#	ARTICLE	IF	CITATIONS
569	Neoadjuvant Therapy in Locally Advanced Renal Cell Carcinoma. , 2023, , 195-229.		0
570	First-Line Systemic Treatment Options for Advanced Renal Cell Carcinoma. , 2023, , 269-292.		0